Bone Ev To Operating Cash Flow from 2010 to 2024
| BBLG Stock | USD 1.25 0.02 1.63% |
EV To Operating Cash Flow | First Reported 2010-12-31 | Previous Quarter 0.19225703 | Current Value 0.2 | Quarterly Volatility 1.3 M |
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Ebitda of 503.6 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
Bone | Ev To Operating Cash Flow |
Latest Bone Biologics' Ev To Operating Cash Flow Growth Pattern
Below is the plot of the Ev To Operating Cash Flow of Bone Biologics Corp over the last few years. It is a valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. Bone Biologics' EV To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
| Ev To Operating Cash Flow | 10 Years Trend |
|
Ev To Operating Cash Flow |
| Timeline |
Bone Ev To Operating Cash Flow Regression Statistics
| Arithmetic Mean | (337,170) | |
| Geometric Mean | 11.76 | |
| Coefficient Of Variation | (387.20) | |
| Mean Deviation | 629,220 | |
| Median | (1.96) | |
| Standard Deviation | 1,305,513 | |
| Sample Variance | 1.7T | |
| Range | 5.1M | |
| R-Value | 0.43 | |
| Mean Square Error | 1.5T | |
| R-Squared | 0.19 | |
| Significance | 0.11 | |
| Slope | 126,420 | |
| Total Sum of Squares | 23.9T |
Bone Ev To Operating Cash Flow History
About Bone Biologics Financial Statements
Bone Biologics stakeholders use historical fundamental indicators, such as Bone Biologics' Ev To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Although Bone Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bone Biologics' assets and liabilities are reflected in the revenues and expenses on Bone Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bone Biologics Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EV To Operating Cash Flow | 0.19 | 0.20 |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out the analysis of Bone Biologics Correlation against competitors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.